The newest weight loss pill is oral semaglutide (Wegovy) 25 mg, approved by the FDA on December 22, 2025, as the first GLP-1 pill specifically cleared for weight loss. It’s the same active ingredient found in the Wegovy injection, but taken as a once-daily tablet instead of a weekly shot. Novo Nordisk plans to launch it in the US in early January 2026.
How the Pill Works
Oral semaglutide belongs to a class of drugs called GLP-1 receptor agonists. Your gut naturally releases GLP-1, a hormone that signals fullness after eating and helps regulate blood sugar. The pill mimics that hormone, binding to the same receptors and amplifying the “I’m full” signal. The result is reduced appetite, smaller portions, and fewer cravings between meals.
This isn’t an entirely new molecule. Oral semaglutide was first approved in 2019 for type 2 diabetes at lower doses (7 mg and 14 mg, sold as Rybelsus). The weight loss version uses a much higher 25 mg dose, which produces significantly greater effects on body weight.
How Much Weight People Lose
The most robust trial data comes from the OASIS 1 study, which tested an even higher 50 mg oral dose in adults with overweight or obesity who didn’t have type 2 diabetes. Over 68 weeks (about 16 months), participants on the pill lost an average of 15.1% of their body weight, compared to 2.4% with a placebo. That’s a difference of roughly 12.7 percentage points.
The results were consistent across different thresholds. About 85% of people on the pill lost at least 5% of their body weight, 69% lost at least 10%, and more than a third (34%) lost 20% or more. Those numbers rival the results seen with injectable Wegovy, which was previously the gold standard.
Pill vs. Injection
For many people, the appeal of a pill over a weekly injection is obvious. But there’s a practical question: does the pill work as well?
In real-world studies comparing the older, lower-dose oral semaglutide to injectable semaglutide for type 2 diabetes, the injectable version produced slightly more weight loss (about 1.6 kg more over 26 weeks), though the difference wasn’t statistically significant. The higher-dose oral formulations now approved for weight loss are designed to close that gap. In clinical trials, the 50 mg oral dose produces weight loss percentages in the same ballpark as the 2.4 mg weekly injection.
The daily pill does come with a specific routine: you take it on an empty stomach with a small sip of water, then wait at least 30 minutes before eating or drinking anything else. This is necessary for the drug to absorb properly. The injection, by contrast, is once a week with no food restrictions.
Common Side Effects
Gastrointestinal symptoms are the most frequent side effects by a wide margin. In the OASIS 1 trial, 80% of participants on the 50 mg pill reported some form of GI issue, compared to 46% on placebo. Nausea, vomiting, diarrhea, and constipation are the usual culprits. Most of these were rated mild to moderate and tended to be worst during the dose-escalation period, when the body is adjusting.
Less common but more serious risks include pancreatitis (inflammation of the pancreas causing abdominal pain), gastroparesis (delayed stomach emptying), bowel obstruction, and gallstone attacks. These are rare but worth knowing about, particularly if you have a history of gallbladder problems or pancreatitis.
What Happens to Muscle Mass
One concern with any significant weight loss, whether from medication, surgery, or dieting, is how much of the lost weight comes from muscle rather than fat. The data on GLP-1 drugs is mixed. Some studies report that lean mass makes up 40% to 60% of total weight lost, while others show it accounting for 15% or less. That’s a wide range, and it likely depends on factors like exercise, protein intake, and individual body composition.
It’s also worth noting that “lean mass” in these studies includes organs, bone, and water stored in fat tissue, not just muscle. So even high lean mass loss numbers don’t translate directly to muscle loss. Still, resistance training and adequate protein are widely recommended alongside these medications to preserve muscle.
Other Pills in Development
Oral semaglutide isn’t the only weight loss pill in the pipeline. Two others are generating significant interest.
Orforglipron, made by Eli Lilly, is a small-molecule GLP-1 pill that doesn’t require the empty-stomach dosing routine of semaglutide. In a Phase 3 trial published in the New England Journal of Medicine, the highest dose (36 mg) produced an average weight loss of 11.2% over 72 weeks, compared to 2.1% with placebo. Lower doses of 6 mg and 12 mg produced losses of 7.5% and 8.4%, respectively. It has not yet received FDA approval.
Amycretin, from Novo Nordisk, takes a different approach. It’s a single molecule that activates both GLP-1 receptors and amylin receptors, targeting two appetite-regulating pathways at once. A Phase 1 trial found it was safe and well tolerated, with gastrointestinal symptoms (again, mostly mild to moderate) being the most common side effects. It’s still early in development, so weight loss data from larger trials isn’t available yet.
Who Qualifies for a Prescription
The eligibility criteria for prescription weight loss medications haven’t changed with the new pill. You typically need a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Cost and Insurance Coverage
Price has been one of the biggest barriers to GLP-1 medications. The list price for Wegovy has been around $1,350 per month, with Zepbound (Eli Lilly’s injectable) at roughly $1,086 per month. A November 2025 White House announcement outlined negotiated pricing through a program called TrumpRx that would bring Wegovy down to $350 per month and Zepbound (along with orforglipron, if approved) to an average of $346 per month.
Perhaps more significantly, these lower prices are expected to allow Medicare to cover Wegovy and Zepbound for patients with obesity and related conditions for the first time. Medicare beneficiaries would pay a co-pay of $50 per month. For the millions of people on Medicare who previously had no coverage for these drugs, that’s a substantial shift. Private insurance coverage varies widely, so checking with your specific plan remains essential.